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Background: To assess the association between 
folic acid deficiency and ischemic heart disease 
Methods:  In this observational  study patients of  
25-65 years of age with newly diagnosed ischemic 
heart disease were included. All the patients on folic 
acid or vitamin B12 therapy, pregnant females, 
patients with any type of malignancy or patients 
with history of megaloblastic anemia were excluded 
from the study. A 3-5ml serum sample for the 
estimation of folic acid levels were obtained. Tests 
were performed using chemiluminescent 
Microparticle Immunoassay (CMIA). Odds ratio was 
determined to measure association between folic 
acid deficiency and ischemic heart disease. 
Results: Folic acid level was assessed both in cases 
and controls, with a mean folic acid level of 
4.19±2.11ng/mL among patients and in controls mean 
folic acid level was 5.05±1.67ng/mL (p-value=0.015). 
Folic acid deficiency was found in 41.7% in cases . 
Odds ratio was 2.347 (95% CI; 1.067, 5.162, p<0.05). 
Conclusion: Folic acid deficiency was found high 
significantly in patients with ischemic heart disease 
as compared to that of controls and risk of ischemic 
heart disease is higher in patients with folic acid 
deficiency. 




It is recognized that folates have a beneficial role in the 
prevention of cardiovascular diseases. For the last few 
years, several studies have reported beneficial impact 
of folic acid on endothelial function, which is a 
surrogate end point for risk of cardiovascular diseases. 
In Pakistani population folic acid deficiency is highly 
prevalent . Folic acid is the parent compound of a 
family of folate compounds.1 Humans cannot 
synthesize folic acid from various metabolites de novo 
and thus have to rely on dietary intake for sufficient 
levels of this vitamin. Citrus fruits, juices, dark green 
leafy vegetables such as spinach, wheat and other 
whole grains, and liver are the rich sources of Folic 
acid.2 Different studies have shown that due to its 
biochemical functions folic acid can reduce 
Homocysteine levels within the blood  and these levels 
can be used as biomarkers for detection of folate 
deficiency.2,3 Clinical and epidemiological studies have 
shown a strong relationship between total plasma 
homocysteine levels and ischemic heart 
disease.4,5These are non communicable diseases 
having association with sedentary life style and 
dietary habits6 and are considered a major health 
problem world wide.7 
Folic acid also reduces atherosclerosis and improves 
endothelial dysfunction and prevents cardiovascular 
diseases.8 Both of these are the major culprits in the 
pathogenesis of ischemic heart disease. Recently 
conducted Indian study shows strong association of 
folic acid deficiency with development of coronary 
artery disease.9 In this study folic acid levels were 
significantly lower in patients of ischemic heart disease 
as compared to healthy controls . 
In Pakistani population folic acid deficiency is highly 
prevalent, which appears to be a major cause of 
hyperhomocysteinemia.10 Lower intake of fresh fruits 
and overcooking of food could be the cause of 
deficiencies of these micronutrients As it is concluded 
in one recent local study that folic acid deficiency 
below 5.5ng/ml leads to increase in levels of 
homocysteine. It could be assumed that folic acid 
deficiency is one of the causes for 
hyperhomocysteinemia in our population.10 
Folic acid therapy on long term basis markedly 
improves the arterial endothelial functions not only in 
patients of unstable coronary artery disease with 
hyperhomocysteinemia but also in healthy cigarette 
smokers.11 Therefore, there is a great need to look into 
the fact that if there exists any association between the 
patients of ischemic heart disease and folic acid 
deficiency. If this is really the fact, then clinicians 
should be advised that simple non toxic, relatively 
inexpensive folic acid supplementation may 
potentially reduce the risk of ischemic heart disease. 
Patients and Methods 
This case control study was conducted at 
HolyFfamilyHospital in department of pathology in 
Journal of Rawalpindi Medical College (JRMC); 2018;22(2):  108-111 
 109 
collaboration with cardiology department ,from 
February to August 2012. Patients of  25-65 years of 
age of either gender having ischemic heart disease 
(Newly diagnosed Patients presenting with sudden 
chest pain radiating to left arm and left side of neck 
with obvious ECG changes (ST Elevation ≥2mm in two 
consecutive chest leads or ≥1mm in two consecutive 
limb leads) or Non-ST Elevation MI (ST Depression, Q 
wave, T wave inversion) and elevated cardiac 
enzymes (TroponinT (positive) and or CKMB(≥25U/L) 
 were included in the study as cases while all healthy 
individuals of matching age and sex attending Medical 
OPD were taken as controls. All the patients on folic 
acid or vitamin B12 therapy, pregnant females, patients 
with any type of malignancy or patients with H/O of 
megaloblastic anemia were excluded from the 
study.Patients were categorized in two groups as cases 
and controls. A 3-5ml Serum sample for the estimation 
of folic acid levels were obtained in gel bottle. All 
samples were processed in pathology laboratory of 
RMC and Allied Hospitals within 24 hours of 
collection. Tests were performed using 
chemiluminescent . Normal folic acid levels were 05-
17ng/mL. Statistically data was analyzed by using 
SPSS version 21. For quantitative variables, like age, 
folic acid levels mean and SD was calculated. 
Independent sample t- test was used to compare folic 
acid levels in two groups. A p-value of <0.05 was 
considered to be significant statistically. Odds ratio 
was determined to measure association between folic 
acid deficiency and ischemic heart disease. 
 
Results 
 Total 120 patients meeting inclusion criteria were 
enrolled in study; 60 in each group. The mean age of 
all cases was 53.85±8.99 and controls were 50.43±9.92 
years . Among cases 88.3% were  male and 11.7% were 
females while among controls there were 90% male 
and 10% females (Table 1). Majority of cases showed  
positive Trop T (Table 2). ST segment elevation was 
seen in 77%( Table 3).Mean folic acid levels in cases 
were 4.19±2.11 (ng/mL) and among controls mean 
folic acid level was 5.05±1.67.The difference was 
statistically significant (Table 4). Mean folic acid level 
was low in cases as compared to controls. i.e. (p-
value=0.015). Among cases, 41.7% were found to be 
folic acid deficient and among controls, folic acid 
deficiency was found in 23.3%. The odds ratio was 
calculated as i.e. 2.347 (95% CI; 1.067, 5.162, p=0.032) 
 
Table-1: Age distribution of  patients and 
controls 
 Cases Controls 
Age (years) 
 53.85±8.99 50.43±9.92 
Sex 
Male 53(88.3%) 54(90%) 
Female 7(11.7%) 6(10%) 
Table 2. Ischemic heart disease -Trop T  
Test Trop T Percentage  of patient 
Positive 87% 
Negative  13% 
Table  3: ECG finding in Cases 
ECG Finding Percentage of Patient  
STEMI 77% 
 NON STEMI 23% 
Table 4. Folic acid level/deficiency in cases  
 and  controls 







Deficient 25(41.7%) 14(23.3%) 0.032 
Normal 35(58.3%) 46(76.7%) 
Odds ratio = 2.347 (95% CI; 1.067, 5.162) 
 
Discussion 
Hyperhomocysteinemia is generally known to be a 
cause of endothelial dysfunction, which further 
predisposes the endothelium to atheroma formation, 
which may lead to thrombo-embolism, causing 
coronary heart disease.12,13 Plasma homocysteine levels 
were found to be high in South Asian population 
living in Great Britain in a recent study carried out in 
the UK. It was supposed that it might be a contributing 
factor to Coronary Heart Disease (CHD) related deaths 
in this group compared with European whites.14,15  
Epidemiological transition has resulted in a new trend 
of morbidity and mortality due to vascular diseases. 
This has predominantly been seen in developing 
countries that account for 80% of the global burden of 
vascular disease16. In these countries patients of 
cardiovascular diseases, with normal  biological 
markers, are not unheard of. This has led to a quest for 
newer causative factors, of which plasma 
homocysteine levels has emerged as a significant 
marker for vascular injury .17-19  It has been studied by 
many scientists that homocysteine decreases in plasma 
with increase in folate levels.10,13,20 
Seema Bhargava in her study assessed the role of  
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serum folic acid and vitaminB12 deficiencies as a 
major cause of high plasma homocysteine levels in 
patients of Northern region of India presenting with 
various pattern of vascular diseases. Folic acid levels 
were  low (though well within the biological reference) 
in the patients of vascular diseases as compared to that 
of controls.9 Statistically significant correlation of 
homocysteine levels with concentration of folic acid 
levels in controls as well as patients was found. In 
controls, homocysteine levels showed a significant 
negative correlation with folic acid levels. Also in 
patients, the negative correlation between 
homocysteine  and folic acid levels was markedly 
significant. In patients of Coronary Artery Disease 
(CAD) and Cerebrovascular disease (CVD), negative 
correlation was significant, but in PVD patients, this 
negative correlation was insignificant. 
According to the results reported by Guo et al plasma 
homocysteine levels in patients of unstable angina 
group was significantly (p-value<0.01) higher as 
compared to that of control group (10.7±5.3 vs. 
19.2±4.9), while folic acid and Vitamin B12 levels were 
also significantly lower (p-value<0.05) (7.0±2.5 vs. 
5.1±2.0). All conventional coronary artery risk factors 
like male sex, cigarette smoking, old age, diabetes 
mellitus, high cholesterol levels and high blood 
pressure were related to the elevated plasma 
homocystiene levels.21,22 
Elevated levels of homocysteine in plasma are having 
association with cardiovascular disease, however the 
precise levels associated with high risk is yet 
controversial. A beneficial effect of folic acid 
interventional therapy on arterial endothelial function 
persists over longer periods is not known. Few studies 
suggest that patients having ≥3 risk factors of coronary 
artery disease, plasma homocysteine concentration 
was found high significantly and folic acid supplement 
therapy may be useful in lowering homocysteine 
levels and so arterial endothelial function can be 
improved.23, 24 Folic acid therapy also improves 
endothelial function significantly in healthy cigarette 
smokers and during pregnancy. 25Homocysteine 
initiates atherogenic effects by stimulating chemokine 
responses in endothelial cells involved in 
atherogenesis and folic acid therapy may down 
regulate these inflammatory responses. 
Supplementation of Folic acid to patients with 
hyperhomocysteinaemia has resulted in a low total 
plasma homocysteine levels. Moreover, a tendency to 
reverse the coagulation status and oxidative stress was 
noted.26-29 Hyperhomocysteinemia is associated with a 
higher risk of ischemic injury to myocardium in 
patients presenting with acute coronary syndrome.  
Elevated plasma concentrations of homocysteine at 
time of admission also strongly predict cardiac events 
at later stage in patients of acute coronary 
syndromes.30-32 It is also predicted that folic acid might 
have direct antioxidant role on the endothelium and 
folic acid could improve endothelial function directly. 
Prolonged folic acid supplementation therapy 
improves arterial endothelial function and has a 
potential role for the prevention of atherosclerosis in 
subjects with hyperhomocysteinaemia.26 ,33 Moens et 
al. recently studied and concluded that folic acid also 
has direct substantial antioxidant effects, not only in 
the human vasculature but also inside myocardium. 
Indeed, it was stated that folic acid by scavenging 
reactive oxygen species which is responsible for its 
oxidation during experimental ischemia and 
reperfusion,  prevents oxidation of BH4 in 
myocardium ,resulting in an improvement of eNOS 
dimerization and coupling. It is therefore assumed that 
decreased bioavailability of 5-MTHF may induce 
uncoupling of eNOS both in the vascular wall as well 
as myocardial tissue.34, 35 
 
Conclusion 
1.Folic acid deficiency was significantly high in 
patients with ischemic heart disease as compared to 
that of controls and risk of ischemic heart disease is 
higher in patients with folic acid deficiency.  
2. Micronutrient supplementation, in known cardiac 
patients, needs consideration . 
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